Akari Therapeutics (FRA:CLA) Debt-to-Asset : 0.37 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Debt-to-Asset?

Akari Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.90 Mil. Akari Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.00 Mil. Akari Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was €2.46 Mil. Akari Therapeutics's debt to asset for the quarter that ended in Sep. 2024 was 0.37.

Akari Therapeutics Debt-to-Asset Historical Data

The historical data trend for Akari Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Debt-to-Asset Chart

Akari Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

Akari Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	0.20	0.37

Competitive Comparison of Akari Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Akari Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akari Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Akari Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Akari Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	3.994
	=	0.00

Akari Therapeutics's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.901	+	0)	/	2.463
	=	0.37

Akari Therapeutics (FRA:CLA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Akari Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Akari Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

AKTX:USA

Address

22 Boston Wharf Road, Boston, MA, USA, 02210

Website

https://www.akaritx.com

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).